390 related articles for article (PubMed ID: 31667718)
1. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
2. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
[TBL] [Abstract][Full Text] [Related]
3. Neurological and Neuropsychological Problems in Tyrosinemia Type I Patients.
van Ginkel WG; Jahja R; Huijbregts SCJ; van Spronsen FJ
Adv Exp Med Biol; 2017; 959():111-122. PubMed ID: 28755189
[TBL] [Abstract][Full Text] [Related]
4. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
[TBL] [Abstract][Full Text] [Related]
6. Pregnancy in an NTBC-treated patient with hereditary tyrosinemia type I.
Kassel R; Sprietsma L; Rudnick DA
J Pediatr Gastroenterol Nutr; 2015 Jan; 60(1):e5-7. PubMed ID: 23838819
[No Abstract] [Full Text] [Related]
7. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.
Gissen P; Preece MA; Willshaw HA; McKiernan PJ
J Inherit Metab Dis; 2003; 26(1):13-6. PubMed ID: 12872835
[TBL] [Abstract][Full Text] [Related]
8. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients.
Masurel-Paulet A; Poggi-Bach J; Rolland MO; Bernard O; Guffon N; Dobbelaere D; Sarles J; de Baulny HO; Touati G
J Inherit Metab Dis; 2008 Feb; 31(1):81-7. PubMed ID: 18214711
[TBL] [Abstract][Full Text] [Related]
9. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC.
Thimm E; Richter-Werkle R; Kamp G; Molke B; Herebian D; Klee D; Mayatepek E; Spiekerkoetter U
J Inherit Metab Dis; 2012 Mar; 35(2):263-8. PubMed ID: 22069142
[TBL] [Abstract][Full Text] [Related]
10. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).
Holme E; Lindstedt S
J Inherit Metab Dis; 1998 Aug; 21(5):507-17. PubMed ID: 9728331
[TBL] [Abstract][Full Text] [Related]
11. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
12. Dietary Considerations in Tyrosinemia Type I.
van Spronsen FJ; van Rijn M; Meyer U; Das AM
Adv Exp Med Biol; 2017; 959():197-204. PubMed ID: 28755197
[TBL] [Abstract][Full Text] [Related]
13. Nontransplant treatment of tyrosinemia.
Holme E; Lindstedt S
Clin Liver Dis; 2000 Nov; 4(4):805-14. PubMed ID: 11232358
[TBL] [Abstract][Full Text] [Related]
14. [Clinical follow up of Chilean patients with tyrosinemia type 1 treated with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-ciclohexanedione (NTBC)].
Raimann E; Cornejo V; Arias C; Cabello JF; Castro G; Fernández E; de la Parra A
Rev Med Chil; 2012 Feb; 140(2):169-75. PubMed ID: 22739945
[TBL] [Abstract][Full Text] [Related]
15. Corneal opacities associated with NTBC treatment.
Ahmad S; Teckman JH; Lueder GT
Am J Ophthalmol; 2002 Aug; 134(2):266-8. PubMed ID: 12140036
[TBL] [Abstract][Full Text] [Related]
16. The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U; Dubois J; Mitchell GA
Adv Exp Med Biol; 2017; 959():75-83. PubMed ID: 28755185
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
18. Tyrosinemia type I: Case series with response to treatment to NTBC.
Shah I; Shah F
Indian J Gastroenterol; 2016 May; 35(3):229-31. PubMed ID: 27109516
[TBL] [Abstract][Full Text] [Related]
19. [Evolution of a case of tyrosinemia type I treated with NTBC].
Ros Viladoms J; Vilaseca Buscà MA; Lambruschini Ferri N; Mas Comas A; González Pascual E; Holme E
An Esp Pediatr; 2001 Mar; 54(3):305-9. PubMed ID: 11262262
[TBL] [Abstract][Full Text] [Related]
20. Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome.
Nobili V; Jenkner A; Francalanci P; Castellano A; Holme E; Callea F; Dionisi-Vici C
Pediatrics; 2010 Jul; 126(1):e235-8. PubMed ID: 20547648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]